USA Nasha Fitter, a tech entrepreneur and CEO of the FOXG1 Research Foundation, discusses the radical shift in drug development led by a new generation of sophisticated parent-entrepreneurs. Following her daughter’s diagnosis with the ultra-rare neurodevelopmental disorder FOXG1 syndrome, Fitter co-founded the FOXG1 Research Foundation and Citizen Health. Her mission: to…
USA Jeff Allen is the President & CEO of Friends of Cancer Research, a research policy and advocacy organisation based in Washington, DC. His organisation works to accelerate the development of cancer therapies through evidence-based policy and collaborative research partnerships. Allen highlights the importance of diagnostics and biomarker testing to help…
France As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition at Lyon 1 University and endocrinologist-diabetologist at Hospices Civils de Lyon, Caussy is a leading voice in metabolic dysfunction-associated steatotic…
France Professor Bana Jabri, Director of the Institut Imagine, brings a transatlantic perspective to advancing genetic medicine. After 25 years in the US, she now leads efforts in France to harness genomic technologies, foster interdisciplinary collaboration, and modernise academic–industry partnerships. Her vision calls for strategic investment, institutional autonomy, and greater risk…
Switzerland Prof. Andrea Alimonti, Director of the Institute of Oncology Research in Bellinzona, a leading Swiss centre focused on translational cancer research, shares his international journey from Rome to New York , Boston, and now Ticino, where he leads a growing, high-impact research institute. Under his leadership, IOR is expanding with…
Switzerland Founded in 1971, the Helmut Horten Foundation has steadily evolved from a discreet philanthropic entity into a pivotal force within Switzerland’s medical research landscape. Today, under the leadership of Alain Robert, the Foundation is navigating a strategic transformation, channelling expanded resources into precision oncology, immunology, and emerging priorities like mental…
Denmark Marianne Pilgaard discusses the evolution of Denmark’s clinical trial landscape, the continued top-tier status of the country in trial activity per capita, and the nation’s commitment to digital innovation and patient-centric research. Pilgaard covers the impact of healthcare reform, regulatory harmonisation, decentralised trials, and the prospects for advanced therapies and…
Switzerland Antoine Geissbühler wears many hats—physician, academic, innovator, and institutional leader—and is at the forefront of digital transformation in healthcare. In this wide-ranging conversation, the Dean of the Faculty of Medicine at the University of Geneva and President of the BioAlps Association shares his journey, insights into Geneva’s unique life sciences…
USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…
Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…
Saudi Arabia Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSHRC), discusses the hospital’s transformation into a world-class medical and research institution, aligning with Saudi Arabia’s Vision 2030. He shares insights into KFSHRC’s pioneering efforts in oncology, transplantation, genetics, and cutting-edge medical technology, as well as its role…
Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…
See our Cookie Privacy Policy Here